Overview
Melorheostosis (also known as Léri disease, Léri melorheostosis, or flowing hyperostosis) is a rare sclerosing bone dysplasia characterized by the progressive thickening and densification of cortical bone, typically affecting one limb or one side of the body. The hallmark radiographic finding is a pattern of dense, irregular cortical hyperostosis that flows along the length of a bone, resembling dripping candle wax on X-ray imaging. The condition most commonly affects the long bones of the upper and lower extremities, though it can also involve the pelvis, spine, ribs, and small bones of the hands and feet. Soft tissue abnormalities, including fibrosis, joint contractures, and overlying skin changes such as scleroderma-like thickening, may accompany the bony changes. Clinical manifestations vary widely in severity. Key symptoms include pain, stiffness, and limited range of motion in affected joints, limb-length discrepancy, muscle weakness or atrophy, and deformity of the affected limb. Some patients may be asymptomatic and diagnosed incidentally on imaging, while others experience significant functional impairment. The condition typically follows a slowly progressive course. Somatic (postzygotic) mosaic mutations in the MAP2K1 gene have been identified as a major cause in many cases, explaining the segmental distribution of the disease. There is no cure for melorheostosis, and treatment is primarily symptomatic and supportive. Pain management with analgesics and anti-inflammatory medications is a mainstay of therapy. Physical therapy and occupational therapy are important for maintaining joint mobility and function. Surgical intervention, including osteotomy, excision of excess bone, joint release, or fasciotomy, may be necessary in cases of severe contracture, nerve compression, or significant functional limitation. Bisphosphonates have been tried in some patients with variable results. Management is best coordinated by a multidisciplinary team including orthopedic surgeons, rheumatologists, and rehabilitation specialists.
Clinical phenotype terms— hover any for plain English:
Sporadic
Usually appears on its own, not inherited from a parent
Variable
Can begin at different ages, from infancy through adulthood
Treatments
No FDA-approved treatments are currently listed for Melorheostosis.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Melorheostosis at this time.
New trials open frequently. Follow this disease to get notified.
Rare Disease Specialist
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Melorheostosis.
Community
No community posts yet. Be the first to share your experience with Melorheostosis.
Start the conversation →Latest news about Melorheostosis
Disease timeline:
New recruiting trial: Natural History, Pathogenesis and Outcome of Melorheostosis A Rare Osteosclerotic Disease
A new clinical trial is recruiting patients for Melorheostosis
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Melorheostosis
What is Melorheostosis?
Melorheostosis (also known as Léri disease, Léri melorheostosis, or flowing hyperostosis) is a rare sclerosing bone dysplasia characterized by the progressive thickening and densification of cortical bone, typically affecting one limb or one side of the body. The hallmark radiographic finding is a pattern of dense, irregular cortical hyperostosis that flows along the length of a bone, resembling dripping candle wax on X-ray imaging. The condition most commonly affects the long bones of the upper and lower extremities, though it can also involve the pelvis, spine, ribs, and small bones of the h
How is Melorheostosis inherited?
Melorheostosis follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
Which specialists treat Melorheostosis?
2 specialists and care centers treating Melorheostosis are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.